Colorectal Cancer

Conversations with Oncology Research Leaders Bridging the Gap between Research and Patient Care

EDITOR

Neil Love, MD

FACULTY

Herbert Hurwitz, MD Peter C Enzinger, MD Al B Benson III, MD



www.ColorectalCancerUpdate.com

Colorectal Cancer Update

A CME Audio Series and Activity

STATEMENT OF NEED/TARGET AUDIENCE

Colorectal cancer is among the most common cancers in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, *Colorectal Cancer Update* utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

- Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment, and
 incorporate these data into management strategies in the local and advanced disease settings.
- · Counsel appropriate patients about the availability of ongoing clinical trials.
- Evaluate the emerging research data on various adjuvant chemotherapy approaches, including the use of
 oxaliplatin-containing regimens and the use of capecitabine or intravenous 5-FU, and explain the absolute
 risks and benefits of these regimens to patients.
- Evaluate emerging research data on various neoadjuvant radiation therapy/chemotherapy approaches to
 rectal cancer and explain the absolute risks and benefits of these regimens to patients.
- Integrate emerging data on biologic therapies into management strategies for patients with advanced colorectal cancer.

PURPOSE OF THIS ISSUE OF COLORECTAL CANCER UPDATE

The purpose of Issue 1 of *Colorectal Cancer Update* is to support these global objectives by offering the perspectives of Drs Hurwitz, Enzinger and Benson on the integration of emerging clinical research data into the management of colorectal cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs or tapes, review the CME information and complete the post-test and evaluation form located in the back of this book or on our website. This CME activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. **ColorectalCancerUpdate.com** includes an easy-to-use, interactive version of this CME activity with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in **blue underlined text**.

TABLE OF CONTENTS

3 EDITOR'S NOTE

75%

5 INTERVIEWS

Herbert Hurwitz, MD

Associate Professor of Medicine Division of Hematology/Oncology Clinical Director, Phase I Program Co-leader, GI Oncology Program Duke University Medical Center Durham, North Carolina

12 Peter C Enzinger, MD

Instructor in Medicine, Harvard Medical School Clinical Director, Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts

19 AI B Benson III, MD

Professor of Medicine Associate Director for Clinical Investigations Robert H Lurie Comprehensive Cancer Center Northwestern University Chicago, Illinois

22 POST-TEST

23 EVALUATION FORM

If you would like to discontinue your complimentary subscription to *Colorectal Cancer Update*, please email us at **Info@ResearchToPractice.net**, or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and stateof-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Marie Bialek, PharmD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Hurwitz — Consulting Fees and Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Genentech BioOncology. Dr Enzinger — Consulting Fees: Daiichi Pharmaceutical Co Ltd, Genentech BioOncology, Pfizer Inc, Sanofi-Aventis. Dr Benson — Consulting Fees and Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

UPCOMING EDUCATIONAL EVENTS

Society of Surgical Oncology Cancer Symposium March 23-26, 2006 San Diego, California Event website: www.surgonc.org

American Association for Cancer Research 97th Annual Meeting April 1-5, 2006 Washington, DC Event website: www.aacr.org

NSABP Group Meeting April 28-May 1, 2006 Denver, Colorado Event website: **www.nsabp.pitt.edu**


2006 ASCO Annual Meeting June 2-6, 2006 Atlanta, Georgia Event website: www.asco.org

American College of Surgeons Oncology Group (ACOSOG) Semiannual Meeting June 22-24, 2006 Chicago, Illinois Event website: www.acosog.org ECOG Semiannual Meeting June 23-25, 2006 Washington, DC Event website: <u>www.ecog.org</u>

UICC World Cancer Congress 2006 July 8-12, 2006 Washington, DC Event website: www.worldcancercongress.org

2nd Annual Oncology Congress October 19-21, 2006 New York, New York Event website: **www.oncologycongress.com**

48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology November 5-9, 2006 Philadelphia, Pennsylvania Event website: <u>www.astro.org</u>



Like all of our audio programs, this issue of *Colorectal Cancer Update* is stuffed like a kishka with scientific content. Herb Hurwitz updates us on the evolving and very encouraging short- and long-term safety data on the anti-VEGF agent bevacizumab; Peter Enzinger comprehensively reviews recent data on adjuvant chemotherapy, particularly trials of oxaliplatin regimens like FOLFOX and FLOX (I prefer lox) and studies of capecitabine, either alone or with oxaliplatin; and Al Benson discusses the background and design of ECOG trial 5202, a critical study evaluating FOLFOX alone or with bevacizumab in Stage II tumors that a central lab at MD Anderson designates as higher risk based on microsatellite instability and 18q deletions.

There is also a Cracker Jack[®]-like special prize included with this program, a report on an exciting patient education project we recently conducted on 150 people with colorectal cancer who reacted to an audio program outlining the risks and benefits of adjuvant chemotherapy.

As discussed on the last issue of this series, our findings provide a number of interesting insights about patient perspectives on this disease. To that end, the enclosed monograph includes a comprehensive look at the survey results and a CD with the 50-minute audio interview with John L Marshall, MD that formed the basis of the survey. Many of Dr Marshall's comments are also excerpted in the print report.


As this note is being composed, our CME group is preparing to travel to San Francisco for the third annual ASCO GI symposium, where we will present a poster outlining many of our major findings from this project. We look forward to onsite and "virtual" feedback regarding this initial foray into patient education and our plan to pilot a "boxed set" of six CDs in 2006 on a variety of patient education issues related to adjuvant systemic therapy for colon cancer.

Of all the fascinating nuggets to come out of this initiative, perhaps my favorite relates to ECOG trial 5202, which randomly assigns patients with higher-risk Stage II tumors to FOLFOX alone or with bevacizumab. Based on Dr Marshall's description of this study, 75 percent of the participants would be willing to enter the study if eligible (1.1, 1.2, 1.3).

Seventy-five percent is an impressive fraction and is far more than the estimated two to three percent of cancer patients nationally who enter clinical trials. Yet, perhaps we should not be too surprised by this finding. Trial 5202 offers participants not only a chance to move the field forward and protect the health of future generations but also the unique opportunity to have their tumor tissue analyzed by one of the best labs in the country. Based on those findings, participants can potentially receive a relatively nontoxic therapeutic agent (bevacizumab) that would not be available off protocol.

Seventy-five percent. Let's tap into this signal and get trials like 5202 and its siblings, NSABP-C-08 and AVANT, done — and done soon. We need more good stuff to talk about on our CME programs in the future, and nothing would be more interesting and encouraging than a trastuzumab-like step forward in adjuvant therapy for colon cancer.

— Neil Love, MD NLove@ResearchToPractice.net January 30, 2006





INTERVIEW

Herbert Hurwitz, MD

Dr Hurwitz is an Associate Professor of Medicine in the Division of Hematology/Oncology, Clinical Director of the Phase I Program and Co-leader of the GI Oncology Program at Duke University Medical Center in Durham, North Carolina.

Tracks 1-20

Track 1	Introduction by Neil Love, MD
Track 2	Bevacizumab-associated hypertension
Track 3	Clinical evaluation of risk for bevacizumab-associated arteriovascular events
Track 4	Potential cardiovascular effects of bevacizumab
Track 5	Potential factors contributing to bowel perforations in studies of bevacizumab
Track 6	Bevacizumab-associated bleeding complications
Track 7	Management of bowel-related complications
Track 8	Timing of bevacizumab adminis- tration and surgery
Track 9	Effect of bevacizumab on hepatic regeneration
Track 10	Role of VEGF inhibition in the adjuvant setting

- Track 11 Potential mechanisms of action of bevacizumab
- Track 12 Clinical use of adjuvant bevacizumab
- Track 13 Administration of bevacizumab beyond chemotherapy in the adjuvant setting
- Track 14 Clinical activity of single-agent bevacizumab
- Track 15 Continuation of bevacizumab after disease progression
- Track 16 Determining the optimal dose of bevacizumab
- Track 17 Evaluation of cetuximab and bevacizumab in combination
- Track 18 Management of bevacizumabrelated side effects
- Track 19 Pharmacoeconomic evaluation of novel therapies
- Track 20 Combining capecitabine with bevacizumab

Select Excerpts from the Interview

📊 Track 2

DR LOVE: Can you summarize the current available database on the safety of bevacizumab?

DR HURWITZ: So far, the main side effect has been hypertension that, in general, is modest and easily manageable. It occurs in about a quarter of all patients, and perhaps one, two or three in 10 patients will need to start receiving blood pressure medication or will need an adjustment to a component of their blood pressure regimen. In general, all blood pressure medica-

tions used to date have been successful. The key issue is close monitoring of the patient.

As oncologists, we used to be able to forget about many general internal medicine issues because cancer mortality was the most important issue for our patients. Now that patients are able to stay on treatments for a year and longer in some cases, management of side effects will be important.

In particular, blood pressure should probably be measured at every clinic visit, and if a clear trend toward increased blood pressure appears, medication should be instituted. Best clinical judgment should be used in the selection and titration of any agent.

DR LOVE: Is anything new in terms of what is known about the mechanism of developing hypertension?

DR HURWITZ: The mechanism is not yet well understood. Preclinical models and some experience in the cardiovascular literature suggest that nitric oxide-mediated mechanisms are likely involved (Shen 1999).

Nitric oxide regulates many processes, including those related to vascular tone, renal hemodynamics and alterations of the renin-angiotensin system. In short, we don't yet know the mechanism of hypertension in these patients. More than likely, some component of all of these processes is involved.

At this time, we don't have enough mechanistic information to drive the selection of one antihypertensive medication over another. Currently, I suggest making this decision based on other reasons one drug may be preferred versus another — the way we do with all patients.

📊 Tracks 4 and 6

DR LOVE: Can you discuss the issues related to bowel perforation and bevacizumab? What have we learned over the last year or two?

DR HURWITZ: The issues related to bowel perforation have many of the same general themes as the arteriovascular event risks. In general, these risks are low.

Several studies of bevacizumab — the large IFL study (Hurwitz 2004), the Phase II 5-FU/leucovorin study (Kabbinavar 2005) and the ECOG second-line FOLFOX with or without bevacizumab study (Giantonio 2005) — have reported a one to two percent risk of GI perforation.

A similar risk is apparent in the historic literature — anywhere between two to five percent of some type of bowel perforation, abscess or fistula formation with the use of chemotherapy alone.

The reasons for those findings are not well understood. These problems have not been observed as commonly in other tumor settings, aside from the ovarian cancer population. This may relate to the fact that GI-toxic regimens are used for colon cancer — more diarrhea and bowel inflammation and

inflammatory wound-healing responses, in general, may predispose these patients to perforation.

DR LOVE: As bevacizumab data accumulate, have we learned anything more about the clinical presentation of these bowel perforations?

DR HURWITZ: For the most part, the presentation of bowel perforation is what you would expect — essentially like an acute abdomen. The definition of bowel perforation, though, has often been very liberal to allow us to detect any event that might be even partially implicated.

As cancer doctors, we're quite used to dealing with the complications of regimens that affect bowel integrity. IFL, FOLFOX, and 5-FU alone all cause diarrhea, and if that gets out of hand, it can lead to an occasional serious or even life-threatening complication.

Patients who have bowel trouble and start to experience serious symptoms should be evaluated urgently, and standard management should be pursued.

📊 Tracks 8-9

DR LOVE: What do we know about patients who require emergent surgery while they're receiving bevacizumab?

DR HURWITZ: The issue of surgery and bevacizumab needs to be broken down into two separate categories. One category includes patients who have major surgery and then receive bevacizumab.

Among patients who've waited at least a month prior to starting bevacizumab and who have healed sufficiently to be cleared by their surgeons, no increased risk of wound-healing complications is apparent. The converse setting, where patients are on bevacizumab and then go to surgery, is a bit more complicated.

The best data come from the IFL study (Hurwitz 2004). Most of the patients going to surgery did so for an urgent or emergent indication — usually major abdominal procedures.

Wound-healing complications ranged from minor to major wound dehiscence or major bruising at the site, and the wound-healing complication risk ranged from about four to 14 percent.

Most complications were manageable — rarely lethal. I would interpret that range in risk to mean that the rate does increase for emergent or urgent indications, such as drainage of an abscess or some other acute issue. That risk is acceptable, and the risk of wound-healing complications should not deter good surgical or interventional management when needed.

For highly elective surgery, one should respect the half-life of the drug, which is about 21 days. One should wait two to three half-lives of the drug — about 40 to 60 days — before elective surgery. This becomes a bit of a risk-benefit ratio, as we have not truly identified the best interval for timing elective

metastatic resection. I think the window for metastatic resections is probably about six weeks following cessation of treatment with bevacizumab.

DR LOVE: With respect to hepatic resection or ablation, what do we know about the effect of bevacizumab on hepatic regeneration?

DR HURWITZ: We don't know a lot about the effect of bevacizumab per se on hepatic regeneration. From clinical and preclinical information, we know that hepatic regeneration is angiogenesis-dependent.

We also know that the majority of hepatic regeneration occurs within a few weeks to a month or so after surgery. Some patients clearly take a little bit longer to regain both liver volume and function after major resection, particularly after a right hepatectomy.

In general, the patient should be well healed, should have normal liver function test results, and should be cleared by his or her surgeon before starting bevacizumab. I think a patient who's completely healed and who has normal liver function test results is a suitable candidate.

Allow two months, perhaps three months for some patients, to recuperate from such surgery — that time frame would be reasonable. For the smaller variations on hepatic resection, such as a left hepatectomy, shorter windows of time may be appropriate.

The administration of bevacizumab after radiofrequency ablation has not been well studied. It is a less invasive procedure, although it does have potential risks. A window of two to four weeks after radiofrequency ablation is probably adequate, provided the patient had no undue complications.

📊 Track 16

DR LOVE: Would you discuss the dosing of bevacizumab?

DR HURWITZ: In the first-line setting, a dose of 5 mg/kg every two weeks, which is a dose intensity of 2.5 mg/kg per week, is the standard of care. Some ongoing studies, mostly of capecitabine-based regimens with oxaliplatin, are using three-week cycles of equivalent dose intensity. Those are 7.5 mg/kg every three weeks, which is essentially the same dosing, particularly given the long half-life of the drug. In the second-line setting, the dose is 10 mg/kg every two weeks.

An older study, the initial randomized Phase II trial (Kabbinavar 2003), evaluated placebo versus 5 mg/kg versus 10 mg/kg. In that study, the 5 mg/kg dose was a little bit better. A number of disclaimers relate to potential imbalances between the 5 and 10 mg groups. However, the 5 mg/kg dose looked good enough to pursue in a Phase III study, and that dose is clearly active. We know the safety profile of that drug in that setting.

Most patients have received bevacizumab in the first-line setting, so we see very few reasons to give bevacizumab in the second-line setting. One can come up with a few scenarios, such as patients having been on a clinical trial without bevacizumab or some complication that caused postponing the treatment. If bevacizumab were truly to be used as a second-line agent, I would use a 10 mg/kg dose. In a hybrid scenario, such as a delayed first-line setting, I would use 5 mg/kg.

📊 Track 17

DR LOVE: What about the combination of cetuximab and bevacizumab — where do you see that heading?

DR HURWITZ: The issue of combining biologics is an interesting one. Right now, preclinical biology suggests synergy when targeting the EGF and VEGF axes. Interesting pilot data came from the BOND-2 trial, which looked at cetuximab with bevacizumab versus cetuximab/bevacizumab and irinotecan (Saltz 2005).

Both arms of that study appeared to do much better than the historical controls of the BOND-1 trial (Cunningham 2004), which evaluated cetuximab monotherapy or cetuximab with irinotecan (2.1). The response rates and time to progression were a lot higher than most of us expected.

For both theoretical and practical reasons, I think the combination is highly worthy of study. Two studies will address this question. The largest study will be a GI Intergroup study of one chemotherapy regimen picked by the investigator — either FOLFOX or FOLFIRI — with the addition of cetuximab, bevacizumab or both (CALGB-C80405). An industry-sponsored study will evaluate FOLFOX/bevacizumab with or without panitumumab, a monoclonal antibody that is essentially a biological cousin of cetuximab.

Efficacy parameter	Cetuximab/irinotecan + bevacizumab ¹ (n = 39)	Cetuximab/irinotecan ² (n = 218)	p-value					
Response rate	38%	23%	0.03					
ime to tumor progression	8.5 months	4 months	S*					
fficacy parameter	Cetuximab/bevacizumab ¹ (n = 35)	Cetuximab alone ² (n = 111)	<i>p</i> -value					
Response rate	23%	11%	0.05					
ime to tumor progression	6.9 months	1.5 months	S*					

SOURCE: Saltz LB et al. Proc ASCO GI Cancers Symposium 2005; Abstract 169b.

📊 Track 20


DR LOVE: Previously, you mentioned the issue of capecitabine with bevacizumab. Is there any reason to believe this combination would be better or worse than bevacizumab with 5-FU?

DR HURWITZ: My expectation is that the regimens would be comparable. Large Phase III studies have been conducted, primarily in Europe, including a FOLFOX versus CAPOX study with or without bevacizumab. This study has completed accrual, and the toxicity results will be available in the next year. Efficacy results will come shortly thereafter, but it may take a while for the survival endpoint data to appear.

In general, capecitabine has tended to look similar to 5-FU, including the capecitabine/oxaliplatin versus infusional 5-FU/oxaliplatin data, without bevacizumab, reported at ASCO this past year (Arkenau 2005; Sastre 2005).

In addition, pilot data from our institution and the larger experience in the TREE-2 study suggest that efficacy should be comparable between capecitabine/oxaliplatin/bevacizumab and the FOLFOX regimen (2.2). That comparability, though, has not yet been validated. As far as clinical management goes, I would still consider an infusional 5-FU regimen with oxaliplatin or irinotecan — FOLFOX or FOLFIRI — as the standard platform on which to add bevacizumab.

For patients who are not candidates for pump therapy, the activity of capecitabine with oxaliplatin and bevacizumab is significant enough that it should be considered as a first-line option. The question of whether or not it's the best option will require the final results of this Phase III study.



SELECT PUBLICATIONS

Arkenau H et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. *Proc ASCO* 2005;<u>Abstract 3507</u>.

Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract

Ellis LM. Bevacizumab. Nat Rev Drug Discov 2005; Suppl: 8-9. Abstract

Ellis LM et al. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. *J Clin Oncol* 2005;23(22):4853-5. No abstract available

Fernando N et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. *Proc ASCO* 2005;<u>Abstract 3556</u>.

Giantonio BJ et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presentation. ASCO GI 2005;Abstract 169a.

Hochster HS et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized "TREE-2" trial. Proc ASCO GI Cancers Symposium 2005; <u>Abstract 241</u>.

Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/ fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. *Proc ASCO* 2005;<u>Abstract 3515</u>.

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. *Am J Health Syst Pharm* 2004;61(21 Suppl 5):21-6. <u>Abstract</u>

Kabbinavar FF et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. *J Clin Oncol* 2005;23(16):3697-705. <u>Abstract</u>

Kabbinavar FF et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. *Proc ASCO* 2004;<u>Abstract 3516</u>.

Kabbinavar F et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. <u>Abstract</u>

Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancers Symposium 2005;<u>Abstract 169b</u>.

Sastre J et al. Preliminary results of a randomized phase III trial of the TTD group comparing capecitabine and oxaliplatin (CapeOx) vs oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). *Proc ASCO* 2005;<u>Abstract 3524</u>.

Scappaticci FA et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-80. Abstract

Shen BQ et al. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999;274(46):33057-63. Abstract

Welles L et al. Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) ("Tree" study). *Proc ASCO* 2004;<u>Abstract 3537</u>.



INTERVIEW

Peter C Enzinger, MD

Dr Enzinger is an Instructor in Medicine at Harvard Medical School and is Clinical Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute in Boston, Massachusetts.

Tracks 1-20

Track 1	Introduction by Dr Love
Track 2	Comparison of NSABP-C-07 and MOSAIC adjuvant trial outcomes
Track 3	Preservation of oxaliplatin dose intensity during adjuvant therapy
Track 4	Use of calcium and magnesium for oxaliplatin- associated neuropathy
Track 5	Dose attenuation or discontinuation for oxaliplatin- associated neuropathy
Track 6	Probability of residual neuropathy after oxaliplatin- containing chemotherapy
Track 7	X-ACT adjuvant trial: Capecitabine versus Mayo Clinic 5-FU regimen
Track 8	Selecting appropriate patients to receive capecitabine as adjuvant therapy
Track 9	Dosing capecitabine in the adjuvant and metastatic settings
Track 10	Differences in North American and European tolerance to capecitabine dosing

- Track 11 Evaluating patients for selection of initial therapy in the metastatic setting
- Track 12 Bevacizumab-associated toxicities
- Track 13 Potential mechanisms of action of bevacizumab

Track 14 Selection of second-line therapy after progression on a bevacizumab-containing regimen

- Track 15
 Side effects and tolerability of bevacizumab and cetuximab
- Track 16 Rationale for evaluating bevacizumab in adjuvant clinical trials
- Track 17 CALGB-C80405: Cetuximab and/ or bevacizumab and FOLFOX or FOLFIRI in the metastatic setting
- Track 18 Therapeutic approach to patients with Stage II disease
- Track 19 Clinical trials evaluating benefit of adjuvant chemotherapy in Stage II disease
- Track 20 Laparoscopic colectomy and number of nodes removed

Select Excerpts from the Interview

📊 Track 2

DR LOVE: Would you discuss the NSABP-C-07 and MOSAIC trials?

DR ENZINGER: Unlike the MOSAIC study (de Gramont 2003; André 2004), the FLOX — or NSABP-C-07 — study (Wolmark 2005) specifically looked at a bolus regimen of 5-FU and leucovorin with or without oxaliplatin. In a sense, it was the traditional Roswell Park regimen with oxaliplatin added to every other treatment.

The accrual for the trial took a little bit longer than that of the MOSAIC study, and the results were reported at a later date. NSABP-C-07 investigators ultimately came to the conclusion that oxaliplatin adds a 4.9 percent absolute benefit when added to 5-FU and leucovorin therapy, almost the same absolute three-year benefit that was found in the MOSAIC study (3.1).

The question is whether we need to give infusional 5-FU or whether we can continue with bolus dosing of 5-FU. Ultimately, I think the infusional 5-FU schedules have lower overall toxicity, but the dose of oxaliplatin in the MOSAIC study was higher, so patients had a higher incidence of neuropathy.

In NSABP-C-07 (Wolmark 2005), a 10 percent difference in Grade III and Grade IV toxicities was evident between the Roswell Park regimen (FU/LV) and the same regimen plus oxaliplatin (FLOX). Seven percent of that difference is due to neuropathy. So the difference in overall toxicity is really only three percent.

The ultimate conclusion is that NSABP-C-07 is a confirmatory trial. It confirms the benefit of oxaliplatin, and it offers oncologists an alternative way of administering this agent in combination with 5-FU and leucovorin, which is reassuring.

I would like to see the overall survival advantage for both trials, and that will probably become evident as deaths increase. When we look at the number of patients who are dying and the patients who are having recurrences, we see that the number of patients with recurrences is increasing.

We're beginning to see a trend in that direction. My suspicion is that it's going to take some time before we actually see an overall survival advantage in either one of these trials.

3.1 Three-Year Disease-Free Survival (DFS) in NSABP-C-07 and MOSAIC

	Three-year DFS (oxaliplatin arm)	Benefit from oxaliplatin	Hazard ratio
NSABP-C-07	76.5%	4.9%	0.79
MOSAIC	78.2%	5.3%	0.77

SOURCES: Wolmark N et al. Presentation. ASCO 2005;<u>Abstract 3500</u>; André T et al. N Engl J Med 2004;350(23):2343-51. <u>Abstract</u>

Track 5

DR LOVE: In what situation would you discontinue oxaliplatin due to neurotoxicity? I hear people talk about discontinuation prior to the development of functional impairment. Is that your approach?

DR ENZINGER: Yes, although I think the more interesting question is when to start attenuating the dose. Do you push the patient to functional impairment

using the full dose, or do you start attenuating early or drop the oxaliplatin as in the OPTIMOX trial (de Gramont 2004)?

There are many ways of doing this in metastatic disease, and I don't think there's one right or wrong way. With many other therapies available, giving treatment for a certain period of time and then switching to something else before these neuropathies arise may be the better approach.

Colleagues who treat lung and breast cancer utilize a set number of cycles, or they treat for a set period of time. It's really only with the GI malignancies, because our patients have such a poor prognosis, that we treat continuously. We probably should begin to consider adopting more of a breast or lung cancer type of approach. In part, I believe that patients will have a better quality of life using that kind of approach.

DR LOVE: FOLFOX in the metastatic setting is very different from using it in the adjuvant setting. In the adjuvant setting, how many patients discontinue the drug? Generally, when is it stopped?

DR ENZINGER: I almost always have to attenuate the oxaliplatin toward the end of the treatment. I need to attenuate oxaliplatin starting around the eighth or ninth treatment in 80 or 90 percent of all patients. I've had to drop oxaliplatin completely in 10 percent.

📊 Track 6

DR LOVE: When patients are about to start receiving FOLFOX for the first time and they ask you about the chances of having some type of residual neuropathy, how do you respond?

DR ENZINGER: I tell them that we don't know whether or not this will occur. The data right now are out to 18 months. But I try to reassure the patient in the sense that the neuropathy — at least according to the MOSAIC study — is very mild. So I tell them that about 24 percent of patients have some residual neuropathy, but only 0.5 percent have debilitating neuropathy. I think those odds are pretty good.

Most patients have experienced some tingling or mild tingling, and that's what I tell my patients to expect. I don't believe that they're going to be left with any debilitating neuropathies. I think the risk for another adverse event is much higher than for long-term debilitating neuropathy.

📊 Track 7

DR LOVE: Another major trial that's had a big impact on clinical decision-making is the X-ACT study, which evaluated capecitabine versus 5-FU (Cassidy 2004; Twelves 2005a, 2005b). Can you summarize that study and discuss your interpretation of the findings?

DR ENZINGER: The X-ACT study evaluated the FDA-approved dose of capecitabine, which is 2,500 mg/m² daily for 14 days straight every three weeks for six months. The standard treatment arm in that trial received the Mayo Clinic 5-FU regimen.

The study was powered to detect relatively small differences in survival and also to look at equivalence between the arms. The three-year results evaluated relapse-free survival, disease-free survival and overall survival.

At the three-year analysis, we saw that the regimen of capecitabine was at least equivalent to the Mayo Clinic 5-FU regimen (3.2). In fact, there was a statistically significant improvement in relapse-free survival, and disease-free survival was right on the edge of significant improvement.

I think overall survival will also show an improvement with further followup. We're seeing the same thing here that we're seeing in the metastatic disease setting — that capecitabine is probably slightly better than what we've observed with bolus 5-FU.

	Number of a median of			
	Capecitabine $(n = 1,004)$	5-FU/LV (n = 983)	HR (95% CI)	<i>p</i> -value E; S
DFS	348	380	0.87 (0.75-1.00)	<0.001; 0.05
RFS	327	362	0.86 (0.74-0.99)	; 0.04
OS	200	227	0.84 (0.69-1.01)	<0.001; 0.07

SOURCE: Twelves C et al. N Engl J Med 2005;352(26):2696-704. Abstract

📊 Track 8

DR LOVE: How do you determine which patients are candidates for capecitabine in the adjuvant setting?

DR ENZINGER: The goalpost for adjuvant treatment has been changed since X-ACT was initiated. Most doctors are now recommending FOLFOX, particularly for patients who are at higher risk for recurrence. So the question now is where capecitabine fits into this whole category.

We know capecitabine had a very nice toxicity profile in the head-to-head comparison with the Mayo Clinic regimen (Twelves 2005b). Toxicities across the board were less than those associated with the Mayo Clinic regimen, except for hand-foot syndrome, with which 17 percent of patients had severe Grade III to Grade IV toxicity.

But the reality is that this will occur during the first cycle. Then you attenuate treatment, and typically, patients will do fine for the rest of the adjuvant course.

Looking at the X-ACT data, a subgroup analysis suggests that patients with N1 disease did better than those with N2 disease, which makes sense to me and would actually fit in nicely with the FOLFOX paradigm.

In my mind, I would say that patients with N2 disease, the patients who have higher risk for recurrence, really should not even be given an option. Those patients should be pushed towards FOLFOX.

Patients who have a lower risk for recurrence, perhaps those with N1 disease, and patients who wish to avoid the neuropathies may actually be good candidates for capecitabine. So perhaps the patients with Stage IIIA disease would do well with capecitabine.

In my own practice, patients with high-risk Stage III disease receive FOLFOX. With low-risk patients, I have an intensive conversation about the risks and benefits of FOLFOX versus the Roswell Park 5-FU regimen versus capecitabine.

DR LOVE: What are the situations in which you'd use the Roswell Park regimen instead of capecitabine?

DR ENZINGER: In my opinion, the Roswell Park regimen is well suited for an elderly patient who needs the social support associated with coming to the office and seeing the nurses. Often, they enjoy the stimulation of coming for a visit.

Capecitabine is a therapy for a business professional, for somebody who believes that adjuvant therapy gets in their way and who wants to have the least number of interruptions possible.

Now we really haven't seen any direct comparisons between Roswell Park and capecitabine. Capecitabine has always been measured against the Mayo Clinic regimen, so I don't know how a toxicity analysis between these other two would work out.

I suspect that Roswell Park would be associated with more diarrhea, more hematologic toxicity and stomatitis, but the difference would be less than when compared with the Mayo Clinic regimen.

DR LOVE: What about patients with Stage II disease?

DR ENZINGER: I think patients with Stage II disease sometimes have a higher risk for recurrence than those with Stage III disease. A patient with Stage IIB colorectal cancer, in my opinion, may have a higher risk for recurrence than someone with Stage IIIA disease, and again, that's where I'd consider all three options.

I tend to push patients towards FOLFOX if they have tumors that have perforated.

📊 Track 16

DR LOVE: The design of randomized trials, both in the metastatic and the adjuvant setting, is becoming a lot more complicated because of all the new agents. What are some of the current research questions that you think are most interesting?

DR ENZINGER: One of the most interesting questions in the adjuvant setting is the role of bevacizumab. It is now shown to be of significant benefit in the metastatic disease setting. Can we duplicate that in the adjuvant setting?

People have argued that we're destroying isolated cancer cells in the adjuvant setting, and isolated cancer cells don't need vasculature — they don't need to recruit oxygen. However, I believe our imaging capabilities are suboptimal.

We're able to detect cancer nodules that are approximately one centimeter in size — it's quite clear that we're not able to detect a cancer nodule less than 0.5 centimeters in size, even in the best-case scenarios. A one-centimeter nodule is significantly larger than the one- to two-millimeter nodule that is the size at which we think the angiogenic switch is being thrown.

If a patient has a tumor nodule between one and 10 millimeters, I believe that's where bevacizumab will probably have its greatest impact. Not only will it have an anti-angiogenic effect, but it'll also promote drug delivery into these fairly large conglomerates of tumor cells. We're talking about many millions of cells in these small tumor nodules.

In designing these trials, I would stratify and look at patients who have poor-risk Stage III disease — the patients who probably have residual tumor nodules, because I think bevacizumab may actually exert its greatest impact or activity in patients with macroscopic residual disease that we just can't see — not in microscopic residual disease.

📊 Track 17


DR LOVE: Can you discuss the upcoming Intergroup trial that will evaluate combined biologic therapy in metastatic disease?

DR ENZINGER: In the upcoming Intergroup study, patients will be randomly assigned to standard chemotherapy (FOLFOX or FOLFIRI) with standard treatment (bevacizumab) or with experimental treatment that includes cetux-imab or cetuximab with bevacizumab (3.3). Based on the data we've seen from the CBI trial (Saltz 2005), many of us expect the arm receiving both biologic agents to win.

The dilemma is that this will be very expensive therapy, but I think that it's going to be very interesting. I think many of us are already tempted to throw everything at these patients — particularly the patients who are at high risk. However, use of both biologics raises financial costs and also toxicity costs.

Randomized Phase III Study of Bevacizumab and/or Cetuximab Plus FOLFOX or FOLFIRI in Untreated Advanced Colorectal Cancer

Protocol IDs: CALGB-C80405, NCT00265850, SWOG-C80405 Target Accrual: 2,300 (Open)



SELECT PUBLICATIONS

3.3

André T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. **Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.** *N Engl J Med* 2004;350(23):2343-51. Abstract

Cassidy J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial. *Proc ASCO* 2004;<u>Abstract 3509</u>.

De Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of Stage II and Stage III colon cancer: Efficacy results with a median follow-up of 4 years. *Proc ASCO* 2005;<u>Abstract 3501</u>.

De Gramont A et al. **OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in** patients with advanced colorectal cancer. *Proc ASCO* 2004;<u>Abstract 3525</u>.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. *Proc ASCO* 2003;<u>Abstract 1015</u>.

Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. *J Clin Oncol* 2005;23(15):3311-3. No abstract available

Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30(4 Suppl 15):5-13. Abstract

Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancer Symposium 2005;<u>Abstract 169b</u>.

Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer. *Proc ASCO* 2005a;<u>Abstract 3521</u>.

Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005b;352(26):2696-704. <u>Abstract</u>

Wolmark N et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. Proc ASCO 2005;<u>Abstract 3500</u>.



INTERVIEW

Al B Benson III, MD

Dr Benson is a Professor of Medicine and Associate Director for Clinical Investigations at the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago, Illinois.

Tracks 1-8

Track 1	Introduction by Dr Love
Track 2	Allelic loss of chromosome 18q and prognosis in colorectal cancer
Track 3	ECOG-E5202: FOLFOX with or without bevacizumab in molecularly identified high-risk Stage II disease
Track 4	ECOG-E5202: Eligibility criteria

Track 5	ECOG-E5202: Duration of bevacizumab therapy
Track 6	ASCO treatment guidelines for Stage II disease
Track 7	Current and potential future strategies to select patients for adjuvant therapy
Track 8	Alternative methods of 5-FU administration

Select Excerpts from the Interview

Track 2

DR LOVE: Can you discuss the background to ECOG trial 5202 in patients with Stage II disease?

DR BENSON: A great deal of emphasis has been placed on laboratory correlative work linked to outcome data from randomized clinical trials. Correlative laboratory studies can be designed in several ways, although the most typical evaluation to date is a retrospective analysis of patient tumor specimens obtained from patients in clinical trials for which outcome data are already available.

One area that has been evaluated extensively — mostly in the retrospective arena — is the phenomenon of 18q deletion, which has been associated with a much poorer prognosis. Under the direction of Stan Hamilton's laboratory, ECOG examined tumor blocks from the primary tumors of individuals who had entered one of two of the early Intergroup adjuvant trials, which were 5-FU based.

Unfortunately, because these are older trials, it was impossible to collect all of the tumor specimens we needed. However, we did have sufficient tumor specimens to conduct a retrospective analysis, which demonstrated that those patients who retain the 18q allele have a far better survivorship than those who do not (Jen 1994).

We also looked at microsatellite instability (MSI) in this series of patients, and it appeared that patients with MSI and evidence of the TGF-beta mutation had a superior survivorship compared to those who did not (Watanabe 2001).

In the cooperative group setting, randomized trials for patients with Stage III disease who receive a 5-FU-based regimen report five-year survival rates near 65 percent. Among patients with 18q deletion — in other words, a poor-risk group — five-year survival was only 50 percent. This correlates with survival statistics for patients who had surgery alone. The implication is that the 5-FU-based regimen had no impact on outcome.

On the other hand, those so-called good-risk patients who retained 18q or had MSI with the TGF-beta mutation had a survival rate of 75 percent at five years. What we don't know in this population is whether this group would have done just as well with surgery alone or if the chemotherapy had some impact. We cannot answer those questions.

📊 Tracks 4-5

DR LOVE: How are the high- and low-risk patients identified in trial 5202?

DR BENSON: The laboratory correlative data were felt to provide enough evidence to conduct a hypothesis-driven trial. The Intergroup elected to evaluate patients' primary tumor specimens for the 18q allele as well as for MSI. The specimens are collected as close to the time of surgery as possible.


When the result is known for the Stage II patients who are asked to participate in the trial, patients are assigned to either the high- or low-risk group. The low-risk group will include those individuals who retain 18q. Our projected survivorship for this group is nearly 90 percent. Of course, this trial will tell us if we're right or wrong in that assumption.

In the high-risk group, another suggestion based on retrospective data indicated that a 5-FU/leucovorin regimen would not be likely to have a major impact. Given the MOSAIC trial data implying that a worse prognostic group tends to receive a greater benefit from FOLFOX (André 2004), it was elected to incorporate FOLFOX into the randomization for the high-risk patients.

So the Intergroup strategy for both colon and rectal cancer is to randomly assign these patients between FOLFOX and FOLFOX with bevacizumab. This is what is being done for Stage II patients in the 5202 trial (4.1).

5202 is now active, and we encourage patients and physicians to participate since it is really the first large-scale prospective randomized trial to determine whether a molecular parameter in colon cancer can aid us in making treatment decisions. In addition, we will be storing tissue to evaluate other potential prognostic and predictive markers once we have outcome data available.

Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium and Fluorouracil with or without Bevacizumab in Patients with Resected Stage II Colon Cancer



* Patients are stratified according to disease stage (IIA versus IIB) and microsatellite stability (stable versus low-grade instability [MSI-L]). Patients at high risk for microsatellite instability (MSI) and loss of heterozygosity (LOH) at chromosome 18q are randomly assigned to one of two treatment arms (arms I and II), whereas patients at low risk for MSI and 18q LOH are assigned to arm III.

SOURCE: NCI Physician Data Query, May 2006.

SELECT PUBLICATIONS

4.1

Allegra C, Sargent DJ. Adjuvant therapy for colon cancer — The pace quickens. N Engl J Med 2005;352(26):2746-8. No abstract available

André T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. **Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.** *N Engl J Med* 2004;350(23):2343-51. **Abstract**

Benatti P et al. Microsatellite instability and colorectal cancer prognosis. *Clin Cancer Res* 2005;11(23):8332-40. <u>Abstract</u>

Benson AB 3^{rd} et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. *J Clin Oncol* 2004;22(16):3408-19. Abstract

Figueredo A et al. Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22(16):3395-407. <u>Abstract</u>

Jen J et al. **Allelic loss of chromosome 18q and prognosis in colorectal cancer.** N Engl J Med 1994;331(4):213-21. <u>Abstract</u>

Popat S et al. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23(3):609-18. <u>Abstract</u>

Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. *EurJ Cancer* 2005;41(14):2060-70. <u>Abstract</u>

Ribic CM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349(3):247-57. <u>Abstract</u>

Sarli L et al. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. *Dis Colon Rectum* 2004;47(9):1467-82. <u>Abstract</u>

Watanabe T et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344(16):1196-206. <u>Abstract</u>

POST-TEST

Colorectal Cancer Update — Issue 1, 2006

QUESTIONS (PLEASE CIRCLE ANSWER):

- Although the mechanism of bevacizumab-associated hypertension is not fully understood, preclinical models suggest that nitric oxide-mediated mechanisms may be involved.
 - a. True
 - b. False
- Studies of bevacizumab in colon cancer patients demonstrate that the rate of bowel perforation ranges from _____.
 - a. 0 to 1 percent
 - b. 8 to 10 percent
 - c. 1 to 2 percent
 - d. 6 to 7 percent
- In the first-line metastatic colorectal setting, the standard dose of bevacizumab for patients with colon cancer is
 - a. 10 mg/kg every two weeks
 - b. 5 mg/kg every two weeks
 - c. 7.5 mg/kg every two weeks
 - d. None of the above
- A comparison of results from the NSABP-C-07 and MOSAIC trials revealed a very similar absolute disease-free survival benefit of approximately ______ when oxaliplatin was added to 5-FU and leucovorin.
 - a. 3 percent
 - b. 5 percent
 - c. 8 percent
- 5. Following treatment with oxaliplatin, the probability of having debilitating residual neuropathy was ______ at 18 months according to data from the MOSAIC trial.
 - a. 5 percent
 - b. 0.5 percent
 - c. 3 percent

- 6. As adjuvant treatment of Stage III disease, the X-ACT trial found that the FDA-approved dose of capecitabine was at least equivalent to the Mayo Clinic regimen.
 - a. True
 - b. False
- 7. The status of chromosome 18q has strong prognostic value in patients with Stage II colorectal cancer.
 - a. True
 - b. False
- 8. Microsatellite instability (MSI) and TGF-beta mutation are associated with superior survival compared to survival among patients with MSI alone.
 - a. True
 - b. False
- ECOG trial 5202 evaluates oxaliplatin plus 5-FU/LV with or without cetuximab in patients with Stage III colon cancer.
 - a. True
 - b. False
- 10. According to the ASCO guidelines, adjuvant chemotherapy should be discussed as an option in patients with Stage II colon cancer.
 - a. True
 - b. False
- 11. The CALGB-C80405 trial is a randomized Phase III trial evaluating FOLFOX or FOLFIRI plus bevacizumab versus ______ in patients with untreated advanced colorectal cancer.
 - a. FOLFOX or FOLFIRI plus cetuximab
 - b. FOLFOX or FOLFIRI plus bevacizumab and cetuximab
 - c. Both a and b
 - d. Neither a nor b

EVALUATION FORM

Colorectal Cancer Update — Issue 1, 2006

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please complete this evaluation form. A certificate of completion will be issued upon receipt of your completed evaluation form.

Please answer the following questions by circling the appropriate rating:								
5 =	4 =	3 =	2=	1 =	N/A =			
Outstanding	Good	Satisfactory	Fair	Poor	Not applicable to this issue of CCU			

GLOBAL LEARNING OBJECTIVES

To what extent does this issue of CCU address the following global learning objectives?

Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment, and incorporate these data into management strategies in the local and advanced disease settings
Counsel appropriate patients about the availability of ongoing clinical trials 5 4 3 2 1 N/A
• Evaluate the emerging research data on various adjuvant chemotherapy approaches, including the use of oxaliplatin-containing regimens and the use of capecitabine or intravenous 5-FU, and explain the absolute risks and benefits of these regimens to patients
• Evaluate emerging research data on various neoadjuvant radiation therapy/chemotherapy approaches to rectal cancer and explain the absolute risks and benefits of these regimens to patients
Integrate emerging data on biologic therapies into management strategies for patients with advanced colorectal cancer

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter				Effectiveness as an educator						
Herbert Hurwitz, MD	5	4	3	2	1		5	4	3	2	1
Peter C Enzinger, MD	5	4	3	2	1		5	4	3	2	1
AI B Benson III, MD	5	4	3	2	1		5	4	3	2	1

OVERALL EFFECTIVENESS OF THE ACTIVITY

Objectives were related to overall purpose/goal(s) of activity5	4	3	2	1	N/A
Related to my practice needs	4	3	2	1	N/A
Will influence how I practice	4	3	2	1	N/A
Will help me improve patient care	4	3	2	1	N/A
Stimulated my intellectual curiosity5	4	3	2	1	N/A
Overall quality of material	4	3	2	1	N/A
Overall, the activity met my expectations5	4	3	2	1	N/A
Avoided commercial bias or influence	4	3	2	1	N/A

EVALUATION FORM

Colorectal Cancer Update — Issue 1, 2006

REQUEST FOR CREDIT — please print clearly

Name:		Speciali	y:	
Degree:				
□ MD □ PharmD □ NP □ BS	🗆 D0	\Box RN	🗆 PA	Other
Medical License/ME Number:	Last 4	Digits of SS	SN (require	ed):
Street Address:			Box/Su	ite:
City, State, Zip:				
Telephone:	Fax:			
Email:				
Research To Practice designates this education Credit(s) [™] . Physicians should only claim cred in the activity.				
I certify my actual time spent to complete this	educationa	l activity to	be	hour(s).
Signature:			Date	2:
Will the information presented cause you to ma	ake any cha	nges in yo	ur practice	?
□ Yes □ No				
If yes, please describe any change(s) you plan	to make in	your practi	ce as a re	sult of this activity:
What other topics would you like to see addres	sed in futu	re educatio	nal progra	ms?
What other faculty would you like to hear interv	viewed in fu	iture educa	itional pro	grams?
Additional comments about this activity:				
FOLLOW-UP				
As part of our ongoing, continuous quality-im surveys to assess the impact of our educational your willingness to participate in such a survey	interventio			
□ Yes, I am willing to participate			0	participate
in a follow-up survey.	I	n a follow-u	p survey.	

To obtain a certificate of completion and receive credit for this activity, please complete the Posttest, fill out the Evaluation Form and mail or fax both to: Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131, FAX 305-377-9998. You may also complete the Post-test and Evaluation online at <u>www.ColorectalCancerUpdate.com/CME</u>. orectal Cancer[™]

U р D Т F A

Fditor Associate Editors

Neil Love, MD Michelle Paley, MD Richard Kaderman, PhD Kathryn Ault Ziel, PhD Writers Lilliam Sklaver Poltorack, PharmD Sally Bogert, RNC, WHCNP Douglas Paley Marie Bialek, PharmD **CMF** Director Michelle Paley, MD **Content Validation** Margaret Peng Director, Creative and Copy Editing Aura Herrmann **Creative Manager** Fernando Rendina **Design Quality Control Director Ben Belin Associate Designer** Maria Agudelo-Schaefer **Graphic Designer** Jason Cunnius Junior Designer Shantia Daniel Senior Production Editor Alexis Oneca Traffic Coordinator Tere Sosa **Copy Editors** Jov Davis Mary DiNunzio Rosemary Hulce Pat Morrissev/Havlin Carol Peschke Susan Petrone Production Manager Patricia Kappes Audio Production Frank Cesarano **Technical Services** Arlv Ledezma Web Master John Ribeiro **Editorial Assistants** Catherine Marshall Patricia McWhorter Christina Rodriguez Ginelle Suarez **Contact Information** Neil Love. MD Research To Practice One Biscavne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net For CME Information Email: CME@ResearchToPractice.net

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by education grants from Genentech BioOncology, Roche Laboratories Inc and Sanofi-Aventis.

The audio tapes, compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use. review of any applicable manufacturer's product information and comparison with recommendations of other authorities.



Copyright © 2006 Research To Practice. This program is supported by education grants from Genentech BioOncology, Roche Laboratories Inc and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: February 2006 Release date: February 2006 Expiration date: February 2007 Estimated time to complete: 3 hours